HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CPU0213

a vasopressor agent; structure in first source

Networked: 14 relevant articles (6 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - CPU0213: 14

Experts

1.	Dai, Yin: 11 articles (06/2009 - 06/2006)
2.	Dai, De-Zai: 10 articles (06/2009 - 06/2006)
3.	Xu, Ming: 3 articles (01/2016 - 06/2008)
4.	Cheng, Yu-Si: 2 articles (05/2009 - 02/2009)
5.	Cui, Bing: 2 articles (02/2009 - 05/2007)
6.	Li, Na: 2 articles (02/2009 - 09/2008)
7.	Tang, Xiao-Yun: 2 articles (07/2008 - 06/2008)
8.	Na, Tao: 2 articles (12/2007 - 05/2007)
9.	Li, Chunyan: 1 article (11/2020)
10.	Li, Xinjun: 1 article (11/2020)

Related Diseases

1.	Cardiomyopathies (Cardiomyopathy) 05/01/2007 - "Endothelin receptor antagonist CPU0213 suppresses ventricular fibrillation in L-thyroxin induced cardiomyopathy." 05/01/2009 - "CPU0213 improved isoprenaline-induced cardiomyopathy by modulating ETA, leptin and FKBP12.6. However, erythromycin increased plasma levels but did not change its effects."
2.	Acute Kidney Injury (Acute Renal Failure) 09/01/2006 - "To examine whether a novel endothelin receptor antagonist, CPU0213, is effective in relieving the acute renal failure (ARF) of septic shock by suppressing the activated endothelin-reactive oxygen species (ET-ROS) pathway and nuclear factor kappa B (NF-kappaB). "
3.	Septic Shock (Toxic Shock Syndrome) 09/01/2006 - "To examine whether a novel endothelin receptor antagonist, CPU0213, is effective in relieving the acute renal failure (ARF) of septic shock by suppressing the activated endothelin-reactive oxygen species (ET-ROS) pathway and nuclear factor kappa B (NF-kappaB). "
4.	Infarction (Infarctions) 11/01/2011 - "CPU0213 pretreatment reduced infarct size as a percentage of the ischemic area by 44.5% (I/R + vehicle: 61.3 ± 3.2 vs I/R + CPU0213: 34.0 ± 5.5%, P < 0.05) and improved ejection fraction by 17.2% (I/R + vehicle: 58.4 ± 2.8 vs I/R + CPU0213: 68.5 ± 2.2%, P < 0.05) compared to vehicle-treated animals. "
5.	Diabetic Retinopathy (Retinopathy, Diabetic) 12/01/2007 - "Total triterpene acid, in terms of pharmacological properties resembling the endothelin receptor antagonist CPU0213, is effective in normalizing expression of the ET system and iNOS in early diabetic retinopathy and vasculaopathy."

Related Drugs and Biologics

1.	Endothelin Receptor Antagonists
2.	tacrolimus binding protein 1B
3.	Endothelins (Endothelin)
4.	Leptin
5.	Isoproterenol (Isoprenaline)
6.	Reactive Oxygen Species (Oxygen Radicals)
7.	NF-kappa B (NF-kB)
8.	Triterpenes
9.	Erythromycin (Erycette)
10.	Acids

Related Therapies and Procedures

1.	Operative Surgical Procedures